Pathophysiology of Vascular Calcification

Current Osteoporosis Reports

Volumn 13, Issue 6, 2015, Pages 372-380

  Chen, Neal X ^a   Moe, Sharon M ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Calcification; Vascular calcification; Vascular smooth muscle cells

Indexed keywords

CALCIUM ION; FETUIN A; MICRORNA; OSTEOCALCIN; OSTEOPROTEGERIN; PYROPHOSPHATE; TRANSCRIPTION FACTOR RUNX2;

BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR MORTALITY; CARTILAGE CELL; CELL DEDIFFERENTIATION; CELL TRANSFORMATION; CELL VACUOLE; CHRONIC KIDNEY DISEASE; DOWN REGULATION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MINERAL METABOLISM; MORBIDITY; NONHUMAN; OSTEOCLAST; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; UPREGULATION; VASCULAR SMOOTH MUSCLE CELL; BONE REMODELING; CELL DIFFERENTIATION; CHRONIC KIDNEY FAILURE; COMPLICATION; CYTOLOGY; METABOLIC BONE DISEASE; METABOLISM; OSTEOCYTE; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

BONE DISEASES, METABOLIC; BONE REMODELING; CELL DIFFERENTIATION; CHONDROCYTES; CORE BINDING FACTOR ALPHA 1 SUBUNIT; HUMANS; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OSTEOCYTES; RENAL INSUFFICIENCY, CHRONIC; VASCULAR CALCIFICATION;

EID: 84945458674     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-015-0293-9     Document Type: Review

References (108)

1. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008;19(2):213–6. doi:10.1681/ASN.2007080854. This review highlights the important factors contributing to vascular calcification in CKD.
2. Ibanez B, Badimon JJ, Garcia MJ. Diagnosis of atherosclerosis by imaging. Am J Med. 2009;122(1 Suppl):S15–25. doi:10.1016/j.amjmed.2008.10.014.
3. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004;95(6):560–7.
4. Proudfoot D, Shanahan CM, Weissberg PL. Vascular calcification: new insights into an old problem [editorial; comment]. J Pathol. 1998;185(1):1–3.
5. Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M. Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996;16(8):978–83.
6. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18(9):1731–40.
7. Chen NX, Moe SM. Vascular calcification: pathophysiology and risk factors. Curr Hypertens Rep. 2012;14(3):228–37. doi:10.1007/s11906-012-0265-8.
8. Mehrotra R, Budoff M, Christenson P, Ipp E, Takasu J, Gupta A, et al. Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney Int. 2004;66(5):2022–31.
9. Mehrotra R, Budoff M, Hokanson JE, Ipp E, Takasu J, Adler S. Progression of coronary artery calcification in diabetics with and without chronic kidney disease. Kidney Int. 2005;68(3):1258–66.
10. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2004;19:1489–96.
11. Orakzai SH, Nasir K, Blaha M, Blumenthal RS, Raggi P. Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals. Atherosclerosis. 2009;202(1):289–95. doi:10.1016/j.atherosclerosis.2008.03.014.
12. Henein MY, Owen A. Statins moderate coronary stenoses but not coronary calcification: results from meta-analyses. Int J Cardiol. 2011;153(1):31–5. doi:10.1016/j.ijcard.2010.08.031.
13. Raggi P, Gongora MC, Gopal A, Callister TQ, Budoff M, Shaw LJ. Coronary artery calcium to predict all-cause mortality in elderly men and women. J Am Coll Cardiol. 2008;52(1):17–23. doi:10.1016/j.jacc.2008.04.004.
14. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438–41.
15. Di Iorio B, Bellasi A. Impact of vascular calcification on QT interval and QT dispersion in CKD and dialysis patients. Am J Nephrol. 2012;35(3):287. doi:10.1159/000336305.
16. Raggi P, Cooil B, Callister TQ. Use of electron beam tomography data to develop models for prediction of hard coronary events. Am Heart J. 2001;141(3):375–82. doi:10.1067/mhj.2001.113220.
17. Budoff MJ, Rader DJ, Reilly MP, Mohler 3rd ER, Lash J, Yang W, et al. Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) study. Am J Kidney Dis. 2011;58(4):519–26. doi:10.1053/j.ajkd.2011.04.024.
18. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68(4):1815–24.
19. Moe SM, O’Neill KD, Reslerova M, Fineberg N, Persohn S, Meyer CA. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant. 2004;19(9):2387–93.
20. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000;15(2):218–23.
21. Gross ML, Meyer HP, Ziebart H, Rieger P, Wenzel U, Amann K, et al. Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and x-ray analysis in renal and nonrenal patients. Clin J Am Soc Nephrol. 2007;2(1):121–34.
22. Nakamura S, Ishibashi-Ueda H, Niizuma S, Yoshihara F, Horio T, Kawano Y. Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol. 2009;4(12):1892–900. doi:10.2215/CJN.04320709.
23. Moe SM, O’Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. 2002;61(2):638–47.
24. Allison MA, Hsi S, Wassel CL, Morgan C, Ix JH, Wright CM, et al. Calcified atherosclerosis in different vascular beds and the risk of mortality. Arterioscler Thromb Vasc Biol. 2012;32(1):140–6. doi:10.1161/ATVBAHA.111.235234.
25. Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ, et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int. 1993;44(5):1071–7.
26. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996;27(3):394–401.
27. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, De Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15(7):1943–51.
28. Barreto DV, Barreto Fde C, Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. Am J Kidney Dis. 2008;52(6):1139–50. doi:10.1053/j.ajkd.2008.06.024.
29. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994;46(3):855–61.
30. Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A, et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab. 2014;99(1):248–55. doi:10.1210/jc.2013-2786.
31. Price PA, June HH, Buckley JR, Williamson MK. SB 242784, a selective inhibitor of the osteoclastic V-H+ATPase, inhibits arterial calcification in the rat. Circ Res. 2002;91(6):547–52.
32. Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O’Neill WC. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int. 2009. doi:10.1038/ki.2008.646.
33. Moe SM, Seifert MF, Chen NX, Sinders RM, Chen X, Duan D, et al. R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD). Nephrol Dial Transplant. 2009. doi:10.1093/ndt/gfp078.
34. Allen MR, Chen NX, Gattone 2nd VH, Chen X, Carr AJ, LeBlanc P, et al. Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. Osteoporos Int. 2013;24(4):1471–81. doi:10.1007/s00198-012-2103-x.
35. Davies MR, Lund RJ, Mathew S, Hruska KA. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol. 2005;16(4):917–28. doi:10.1681/ASN.2004100835.
36. Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int. 2014;85(1):142–50. doi:10.1038/ki.2013.271.
37. Lomashvili KA, Wang X, O’Neill WC. Role of local versus systemic vitamin d receptors in vascular calcification. Arterioscler Thromb Vasc Biol. 2014;34(1):146–51. doi:10.1161/ATVBAHA.113.302525.
38. Murshed M, Harmey D, Millan JL, McKee MD, Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev. 2005;19(9):1093–104.
39. Moe SM, Duan D, Doehle BP, O’Neill KD, Chen NX. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int. 2003;63(3):1003–11.
40. Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation. 2008;118(17):1748–57. doi:10.1161/CIRCULATIONAHA.108.783738.
41. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation [see comments]. Cell. 1997;89(5):747–54. This paper clearly demosntrated the role of RUNX2/Cbfa1 in the osteoblast differenctiation and therefore the marker for transformation of vascuar smooth msucel cells.
42. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89(12):1147–54.
43. Speer MY, Yang HY, Brabb T, Leaf E, Look A, Lin WL, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res. 2009;104(6):733–41. doi:10.1161/CIRCRESAHA.108.183053.
44. Heath JM, Sun Y, Yuan K, Bradley WE, Litovsky S, Dell’Italia LJ, et al. Activation of AKT by O-linked N-acetylglucosamine induces vascular calcification in diabetes mellitus. Circ Res. 2014;114(7):1094–102. doi:10.1161/CIRCRESAHA.114.302968.
45. Monk BA, George SJ. The effect of ageing on vascular smooth muscle cell behaviour—a mini-review. Gerontology. 2014. doi:10.1159/000368576.
46. Shanahan CM. Mechanisms of vascular calcification in CKD-evidence for premature ageing? Nat Rev Nephrol. 2013;9(11):661–70. doi:10.1038/nrneph.2013.176.
47. Crouthamel MH, Lau WL, Leaf EM, Chavkin NW, Wallingford MC, Peterson DF, et al. Sodium-dependent phosphate cotransporters and phosphate-induced calcification of vascular smooth muscle cells: redundant roles for PiT-1 and PiT-2. Arterioscler Thromb Vasc Biol. 2013;33(11):2625–32. doi:10.1161/ATVBAHA.113.302249.
48. Chen NX, Duan D, O’Neill KD, Wolisi GO, Koczman JJ, Laclair R, et al. The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells. Kidney Int. 2006;70:1046–53.
49. Kapustin AN, Davies JD, Reynolds JL, McNair R, Jones GT, Sidibe A, et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res. 2011;109(1):e1–12. doi:10.1161/CIRCRESAHA.110.238808.
50. Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK, et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int. 2003;64(2):441–50.
51. Cozzolino M, Dusso AS, Liapis H, Finch J, Lu Y, Burke SK, et al. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol. 2002;13(9):2299–308.
52. Moe SM, Chen NX, Seifert MF, Sinders RM, Duan D, Chen X, et al. A rat model of chronic kidney disease-mineral bone disorder. Kidney Int. 2009;75(2):176–84. doi:10.1038/ki.2008.456.
53. Neves KR, Graciolli FG, dos Reis LM, Graciolli RG, Neves CL, Magalhaes AO, et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int. 2007;71(12):1262–70.
54. Graciolli FG, Neves KR, dos Reis LM, Graciolli RG, Noronha IL, Moyses RM, et al. Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia. Nephrol Dial Transplant. 2009;24(5):1416–21. doi:10.1093/ndt/gfn686.
55. Shroff R, Long DA, Shanahan C. Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol. 2013;24(2):179–89. doi:10.1681/ASN.2011121191.
56. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15(11):2857–67. doi:10.1097/01.ASN.0000141960.01035.28.
57. Chen NX, O’Neill KD, Chen X, Moe SM. Annexin-mediated matrix vesicle calcification in vascular smooth muscle cells. J Bone Miner Res. 2008;23(11):1798–805. doi:10.1359/jbmr.080604.
58. Ewence AE, Bootman M, Roderick HL, Skepper JN, McCarthy G, Epple M, et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res. 2008;103(5):e28–34. doi:10.1161/CIRCRESAHA.108.181305.
59. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
60. Xin M, Small EM, Sutherland LB, Qi X, McAnally J, Plato CF, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 2009;23(18):2166–78. doi:10.1101/gad.1842409.
61. Leopold JA. MicroRNAs regulate vascular medial calcification. Cells. 2014;3(4):963–80. doi:10.3390/cells3040963.
62. Chen NX, Kiattisunthorn K, O’Neill KD, Chen X, Moorthi RN, Gattone 2nd VH, et al. Decreased microRNA is involved in the vascular remodeling abnormalities in chronic kidney disease (CKD). PLoS One. 2013;8(5):e64558. doi:10.1371/journal.pone.0064558.
63. Goettsch C, Rauner M, Pacyna N, Hempel U, Bornstein SR, Hofbauer LC. miR-125b regulates calcification of vascular smooth muscle cells. Am J Pathol. 2011;179(4):1594–600. doi:10.1016/j.ajpath.2011.06.016.
64. Cui RR, Li SJ, Liu LJ, Yi L, Liang QH, Zhu X, et al. MicroRNA-204 regulates vascular smooth muscle cell calcification in vitro and in vivo. Cardiovasc Res. 2012;96(2):320–9. doi:10.1093/cvr/cvs258.
65. Balderman JA, Lee HY, Mahoney CE, Handy DE, White K, Annis S, et al. Bone morphogenetic protein-2 decreases microRNA-30b and microRNA-30c to promote vascular smooth muscle cell calcification. J Am Heart Assoc. 2012;1(6):e003905. doi:10.1161/JAHA.112.003905.
66. Gui T, Zhou G, Sun Y, Shimokado A, Itoh S, Oikawa K, et al. MicroRNAs that target Ca(2+) transporters are involved in vascular smooth muscle cell calcification. Lab Invest. 2012;92(9):1250–9. doi:10.1038/labinvest.2012.85.
67. Goettsch C, Hutcheson JD, Aikawa E. MicroRNA in cardiovascular calcification: focus on targets and extracellular vesicle delivery mechanisms. Circ Res. 2013;112(7):1073–84. doi:10.1161/CIRCRESAHA.113.300937.
68. Chaturvedi P, Chen NX, O’Neill K, McClintick JN, Moe SM, Janga SC. Differential miRNA expression in cells and matrix vesicles in vascular smooth muscle cells from rats with kidney disease. PLoS One. 2015;10(6):e0131589. doi:10.1371/journal.pone.0131589.
69. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int. 2009;75(9):890–7. doi:10.1038/ki.2008.644. This paper described the importance and mechanism of phosphorus in the development of vascularcalcification.
70. Trombetti A, Stoermann C, Chevalley T, Van Rietbergen B, Herrmann FR, Martin PY, et al. Alterations of bone microstructure and strength in end-stage renal failure. Osteoporos Int. 2012. doi:10.1007/s00198-012-2133-4.
71. Dautova Y, Kozlova D, Skepper JN, Epple M, Bootman MD, Proudfoot D. Fetuin-a and albumin alter cytotoxic effects of calcium phosphate nanoparticles on human vascular smooth muscle cells. PLoS One. 2014;9(5):e97565. doi:10.1371/journal.pone.0097565.
72. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, et al. Association of low fetuin-a (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361(9360):827–33.
73. Moe SM. Disorders of calcium, phosphorus, and magnesium. Am J Kidney Dis. 2005;45(1):213–8.
74. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, et al. Low fetuin-a levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int. 2005;67(6):2383–92.
75. Schoppet M, Rauner M, Benner J, Chapurlat R, Hofbauer LC, Szulc P. Serum fetuin-a levels and abdominal aortic calcification in healthy men—the STRAMBO study. Bone. 2015;79:196–202. doi:10.1016/j.bone.2015.06.004.
76. Reynolds JL, Skepper JN, McNair R, Kasama T, Gupta K, Weissberg PL, et al. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol. 2005;16(10):2920–30. doi:10.1681/ASN.2004100895.
77. Denecke B, Graber S, Schafer C, Heiss A, Woltje M, Jahnen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-a. Biochem J. 2003;376(Pt 1):135–45.
78. Westenfeld R, Schafer C, Kruger T, Haarmann C, Schurgers LJ, Reutelingsperger C, et al. Fetuin-a protects against atherosclerotic calcification in CKD. J Am Soc Nephrol. 2009;20(6):1264–74. doi:10.1681/ASN.2008060572.
79. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386(6620):78–81.
80. Beazley KE, Lima F, Borras T, Nurminskaya M. Attenuation of chondrogenic transformation in vascular smooth muscle by dietary quercetin in the MGP-deficient mouse model. PLoS One. 2013;8(9):e76210. doi:10.1371/journal.pone.0076210.
81. Cranenburg EC, Vermeer C, Koos R, Boumans ML, Hackeng TM, Bouwman FG, et al. The circulating inactive form of matrix Gla protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res. 2008;45(5):427–36. doi:10.1159/000124863.
82. McCabe KM, Booth SL, Fu X, Shobeiri N, Pang JJ, Adams MA, et al. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int. 2013;83(5):835–44. doi:10.1038/ki.2012.477.
83. Westenfeld R, Krueger T, Schlieper G, Cranenburg EC, Magdeleyns EJ, Heidenreich S, et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis. 2012;59(2):186–95. doi:10.1053/j.ajkd.2011.10.041.
84. Schurgers LJ. Vitamin K: key vitamin in controlling vascular calcification in chronic kidney disease. Kidney Int. 2013;83(5):782–4. doi:10.1038/ki.2013.26.
85. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med. 2001;79(5–6):243–53.
86. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000;192(4):463–74.
87. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(−/−) mice. Circulation. 2008;117(3):411–20. doi:10.1161/CIRCULATIONAHA.107.707380.
88. Callegari A, Coons ML, Ricks JL, Yang HL, Gross TS, Huber P, et al. Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification. Arterioscler Thromb Vasc Biol. 2013;33(11):2491–500. doi:10.1161/ATVBAHA.113.301755.
89. Deuell KA, Callegari A, Giachelli CM, Rosenfeld ME, Scatena M. RANKL enhances macrophage paracrine pro-calcific activity in high phosphate-treated smooth muscle cells: dependence on IL-6 and TNF-alpha. J Vasc Res. 2012;49(6):510–21. doi:10.1159/000341216.
90. Lomashvili KA, Garg P, Narisawa S, Millan JL, O’Neill WC. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int. 2008;73(9):1024–30. doi:10.1038/ki.2008.26.
91. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Hohne W, et al. Mutations in ENPP1 are associated with ‘idiopathic’ infantile arterial calcification. Nat Genet. 2003;34(4):379–81. doi:10.1038/ng1221.
92. Lomashvili KA, Khawandi W, O’Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol. 2005;16(8):2495–500.
93. O’Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant. 2009. doi:10.1093/ndt/gfp362.
94. Lomashvili KA, Narisawa S, Millan JL, O’Neill WC. Vascular calcification is dependent on plasma levels of pyrophosphate. Kidney Int. 2014. doi:10.1038/ki.2013.521.
95. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–17.
96. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20):1478–83.
97. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112(17):2627–33.
98. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol. 2006;1(4):697–703. doi:10.2215/cjn.00560206.
99. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int. 2004;66(6):2293–9.
100. Balci M, Kirkpantur A, Gulbay M, Gurbuz OA. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodial Int. 2010;14(4):425–32. doi:10.1111/j.1542-4758.2010.00480.x.
101. Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int. 2011. doi:10.1007/s00198-011-1838-0.
102. Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int. 2013;83(6):1159–68. doi:10.1038/ki.2013.3.
103. Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial. 2007;20(4):302–8. doi:10.1111/j.1525-139X.2007.00308.x.
104. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45–51.
105. El-Abbadi MM, Pai AS, Leaf EM, Yang HY, Bartley BA, Quan KK, et al. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int. 2009;75(12):1297–307. doi:10.1038/ki.2009.83.
106. Takei Y, Yamamoto H, Sato T, Otani A, Kozai M, Masuda M, et al. Stanniocalcin 2 is associated with ectopic calcification in alpha-klotho mutant mice and inhibits hyperphosphatemia-induced calcification in aortic vascular smooth muscle cells. Bone. 2012;50(4):998–1005. doi:10.1016/j.bone.2012.01.006.
107. Lindberg K, Olauson H, Amin R, Ponnusamy A, Goetz R, Taylor RF, et al. Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS One. 2013;8(4):e60658. doi:10.1371/journal.pone.0060658.
108. Jimbo R, Kawakami-Mori F, Mu S, Hirohama D, Majtan B, Shimizu Y, et al. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of klotho deficiency. Kidney Int. 2014;85(5):1103–11. doi:10.1038/ki.2013.332.